文献速递泌尿生殖技术与安全PETCT

韩国晚期转移性去势抵抗性前列腺癌患者的FDG与前列腺特异性膜抗原PET/CT表现描述

Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Korean J Radiol · 2024-01-01

本研究描述了42例抗雄激素治疗和化疗失败后行配对FDG与PSMA PET/CT的韩国晚期mCRPC患者。基于患者分析,39例为PSMA+/FDG+,2例为PSMA+/FDG-,1例为PSMA-/FDG+;54.8%的患者至少一处肿瘤FDG摄取高于PSMA,28.6%呈FDG优势模式。

要点

  • 多数晚期mCRPC患者FDG与PSMA PET/CT均阳性,但摄取模式存在异质性。
  • 54.8%(23/42)患者至少一处肿瘤病灶FDG摄取高于PSMA摄取。
  • 28.6%(12/42)患者呈FDG优势模式,其诊断后时间更短且AST、LDH更高。

核心结论

  • 大多数晚期mCRPC患者FDG和PSMA PET/CT均阳性,但摄取模式多样;54.8%患者至少一处肿瘤FDG摄取高于PSMA,28.6%呈FDG优势模式。

研究设计与样本

  • 对42例连续纳入的晚期mCRPC患者(抗雄激素治疗和化疗失败后为制定治疗方案)行配对FDG和PSMA PET/CT检查;以视觉判读病灶摄取高于肝脏为阳性,按患者和肿瘤部位(前列腺床、淋巴结、骨、内脏)记录。

关键影像表现/征象

  • 基于患者分析:PSMA+/FDG- 2例,PSMA-/FDG+ 1例,PSMA+/FDG+ 39例。
  • 基于部位分析的不一致率(PSMA+/FDG-或PSMA-/FDG+):前列腺/床9.5%(4/42),淋巴结11.9%(5/42),骨9.5%(4/42),内脏11.9%(5/42)。
  • 54.8%(23/42)患者至少一处肿瘤部位FDG摄取高于PSMA摄取。
  • FDG PET/CT总肿瘤体积大于PSMA PET/CT(FDG优势模式)者占28.6%(12/42)。

诊断标准与关键数值

  • 病灶FDG或PSMA摄取强度高于肝脏(视觉判读)定义为阳性。
  • FDG优势模式定义为FDG PET/CT上总肿瘤体积大于PSMA PET/CT上的总肿瘤体积。

临床应用与阅片要点

  • FDG优势模式患者诊断后时间更短(中位25个月 vs 62个月,P=0.049),AST更高(中位28.5 vs 22.5,P=0.027),LDH更高(中位341.5 vs 224.5,P=0.010)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: We aimed to describe the [18F]fluorodeoxyglucose (FDG) and prostate-specific membrane antigen (PSMA) PET/CT findings in Korean men with advanced metastatic castration-resistant prostate cancer (mCRPC).

MATERIALS AND METHODS: The results of paired FDG and PSMA PET/CT examinations performed in 42 consecutive men with prostate cancer for treatment planning after failure of anti-androgen therapy and chemotherapy were studied. Tumor lesions with FDG or PSMA uptake intensity higher than that of the liver on visual review were considered positive and noted per patient and tumor site (prostate bed, lymph node, bone, and visceral organ). The presence of unequivocally discordant FDG and PSMA uptake patterns in tumor lesions was assessed. Patients were grouped according to the total tumor volume as seen on each PET/CT scan, and the clinical findings between the patient groups were compared using the Mann-Whitney U test.

RESULTS: On patient-based analysis, the image findings were PSMA+/FDG- in 2 patients, PSMA-/FDG+ in one, and PSMA+/FDG+ in 39 patients. On site-based analysis, the discordance (PSMA+/FDG- or PSMA-/FDG+) rate was 9.5% (4/42) for prostate/bed, 11.9% (5/42) for lymph nodes, 9.5% (4/42) for bones, and 11.9% (5/42) for visceral organs. FDG uptake was higher than PSMA uptake in at least one tumor site in 54.8% (23/42) of patients. Patients with greater total tumor volume on FDG PET/CT than that on PSMA PET/CT ("FDG-dominant pattern") accounted for 28.6% (12/42), and they had significantly shorter time from diagnosis (median 25 months vs. 62 months, P = 0.049), and higher aspartate aminotransferase (median 28.5 vs. 22.5, P = 0.027) and lactate dehydrogenase (median 341.5 vs. 224.5, P = 0.010) levels.

CONCLUSION: Most patients with advanced mCRPC had tumors with positive findings on both FDG and PSMA PET/CT. However, the uptake patterns varied; 54.8% of the patients had tumor(s) with FDG uptake greater than PSMA uptake, and FDG-dominant pattern was noted in 28.6% of the patients.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Na SJ, Ha S, Kim IH, et al. Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer. Korean J Radiol. 2024. PMID: 39473093. doi:10.3348/kjr.2024.0439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。